Table 1 Patient characteristics
|  | All patients N = 309 | Patients without MACE N = 267 | Patients with MACE N = 42 | *P-value |
|---|---|---|---|---|
Clinical variables | ||||
 Age, years | 69 ± 9 | 69 ± 9 | 70 ± 9 | 0.45 |
 Male | 244 (78%) | 212 (79%) | 32 (76%) | 0.79 |
 BMI, kg/m2 | 25 ± 4 | 25 ± 3 | 25 ± 4 | 0.87 |
 Hypertension | 193 (62%) | 163 (61%) | 30 (71%) | 0.26 |
 Dyslipidemia | 180 (58%) | 148 (55%) | 32 (76%) | 0.017 |
 Smoking | 31 (10%) | 25 (9%) | 6 (14%) | 0.47 |
 History of CAD | 176 (56%) | 147 (55%) | 29 (69%) | 0.12 |
Blood tests | ||||
 HbA1c, % | 6.8 ± 0.9 | 6.8 ± 0.9 | 6.8 ± 0.9 | 0.97 |
 LDL cholesterol | 99 ± 29 | 98 ± 29 | 104 ± 30 | 0.21 |
 eGFR | 67 ± 16 | 68 ± 15 | 62 ± 17 | 0.048 |
Medications | ||||
 Aspirin | 183 (59%) | 152 (57%) | 31 (74%) | 0.057 |
 Beta-blocker | 124 (40%) | 105 (39%) | 19 (45%) | 0.58 |
 Statin | 171 (55%) | 139 (52%) | 32 (76%) | 0.006 |
 Calcium channel blocker | 116 (37%) | 100 (37%) | 16 (38%) | 0.92 |
 Nitroglycerin | 101 (33%) | 81 (30%) | 20 (48%) | 0.041 |
 ACE inhibitor/ARB | 124 (38%) | 104 (39%) | 20 (47%) | 0.37 |
 Oral hypoglycemic agent | 220 (71%) | 190 (71%) | 30 (71%) | 0.89 |
 Insulin | 21 (7%) | 16 (6%) | 5 (12%) | 0.27 |
CMR variables | ||||
 LVEDV, mL | 129 ± 46 | 128 ± 41 | 137 ± 67 | 0.23 |
 LVESV, mL | 57 ± 36 | 55 ± 34 | 69 ± 49 | 0.022 |
 LV mass, g | 96 ± 25 | 94 ± 26 | 102 ± 24 | 0.063 |
 LVEF, % | 58 ± 12 | 59 ± 12 | 53 ± 13 | 0.003 |
 Presence of LGE | 143 (46%) | 115 (43%) | 28 (67%) | 0.007 |
 Presence of ischemia | 124 (40%) | 87 (33%) | 37 (88%) | < 0.001 |